Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU1-83P is a pseudogene member of the U1 small nuclear RNA gene family and is annotated as "RNA, U1 small nuclear 83, pseudogene." U1 small nuclear RNAs (snRNAs) are essential components of the spliceosome, where they play a central role in the recognition of pre-mRNA 5′ splice sites and initiation of splicing. However, pseudogenes like RNU1-83P are characterized by sequence similarity to functional U1 genes but typically have mutations or imperfections that prevent them from producing a functional snRNA molecule[1][2][4][5]. Pseudogenes do not encode proteins and generally lack direct or specific biological function by themselves. Some variant U1 snRNA pseudogene transcripts might be expressed in certain contexts and could potentially modulate gene expression through roles in RNA regulation, but there is no curated or standardized evidence for a functional impact or therapeutic targetability for RNU1-83P specifically[1]. Overall, RNU1-83P is not considered a therapeutic target, receptor, enzyme, or protein, nor is it associated with pharmacological agents or clear disease relevance. It is more accurately described as a non-coding RNA pseudogene[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 83, pseudogene (RNU1-83P).